Comments on "Whole lung irradiation as a novel treatment for COVID-19: Interim results of an ongoing phase 2 trial in India".
作者信息
Ghaznavi Hamid, Bevelacqua Joseph J, Mortazavi S A R, Mortazavi S M J, Welsh James S
机构信息
Department of Radiology, Faculty of Paramedical Sciences, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Bevelacqua Resources, Richland, United States.
出版信息
Radiother Oncol. 2022 Feb;167:323-324. doi: 10.1016/j.radonc.2021.12.002. Epub 2021 Dec 8.
Abstract
摘要
相似文献
1
Comments on "Whole lung irradiation as a novel treatment for COVID-19: Interim results of an ongoing phase 2 trial in India".对《全肺照射作为COVID-19的一种新疗法：印度一项正在进行的2期试验的中期结果》的评论
Radiother Oncol. 2022 Feb;167:323-324. doi: 10.1016/j.radonc.2021.12.002. Epub 2021 Dec 8.
2
Response to comments on "Whole lung irradiation as a novel treatment for COVID-19: Interim results of an ongoing phase 2 trial in India".对关于“全肺照射作为COVID-19的一种新治疗方法：印度一项正在进行的2期试验的中期结果”评论的回应
Radiother Oncol. 2022 Feb;167:325. doi: 10.1016/j.radonc.2021.12.001. Epub 2021 Dec 8.
3
Whole lung irradiation as a novel treatment for COVID-19: Interim results of an ongoing phase 2 trial in India.全肺照射作为新型冠状病毒肺炎的一种新治疗方法：印度一项正在进行的2期试验的中期结果
Radiother Oncol. 2021 Oct;163:83-90. doi: 10.1016/j.radonc.2021.08.001. Epub 2021 Aug 12.
4
Low-dose whole-lung radiation for COVID-19 pneumonia: Planned day 7 interim analysis of a registered clinical trial.低剂量全肺照射治疗 COVID-19 肺炎：一项注册临床试验的计划第 7 天的中期分析。
Cancer. 2020 Dec 1;126(23):5109-5113. doi: 10.1002/cncr.33130. Epub 2020 Sep 28.
5
Comments on "Whole lung irradiation as a novel treatment for COVID-19: Final results of the prospective randomized trial (WINCOVID trial)".对《全肺照射作为COVID-19的一种新治疗方法：前瞻性随机试验（WINCOVID试验）的最终结果》的评论
Radiother Oncol. 2022 May;170:244-245. doi: 10.1016/j.radonc.2022.02.035. Epub 2022 Mar 5.
6
Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India.DNA SARS-CoV-2 疫苗（ZyCoV-D）的有效性、安全性和免疫原性：在印度进行的 3 期、随机、双盲、安慰剂对照研究的中期疗效结果。
Lancet. 2022 Apr 2;399(10332):1313-1321. doi: 10.1016/S0140-6736(22)00151-9.
7
Low-Dose Whole-Lung Irradiation for COVID-19 Pneumonia: Short Course Results.低剂量全肺照射治疗 COVID-19 肺炎：短期疗程结果。
Int J Radiat Oncol Biol Phys. 2020 Dec 1;108(5):1134-1139. doi: 10.1016/j.ijrobp.2020.07.026. Epub 2020 Jul 21.
8
Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.新型冠状病毒灭活疫苗在安全性和免疫原性方面的效果：两项随机临床试验的中期分析。
JAMA. 2020 Sep 8;324(10):951-960. doi: 10.1001/jama.2020.15543.
9
Response to "Comments on whole lung irradiation as a novel treatment for COVID-19: Final results of the prospective randomized trial (WINCOVID trial)".对《关于全肺照射作为COVID-19的一种新治疗方法：前瞻性随机试验（WINCOVID试验）的最终结果》的回应
Radiother Oncol. 2022 May;170:246. doi: 10.1016/j.radonc.2022.02.037. Epub 2022 Mar 10.
10
Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study.印度基于灭活病毒的 SARS-CoV-2 疫苗 BBV152 的有效性：一项病例对照研究。
Lancet Infect Dis. 2022 Mar;22(3):349-356. doi: 10.1016/S1473-3099(21)00674-5. Epub 2021 Nov 23.
引用本文的文献
1
Response to comments on "Whole lung irradiation as a novel treatment for COVID-19: Interim results of an ongoing phase 2 trial in India".对关于“全肺照射作为COVID-19的一种新治疗方法：印度一项正在进行的2期试验的中期结果”评论的回应
Radiother Oncol. 2022 Feb;167:325. doi: 10.1016/j.radonc.2021.12.001. Epub 2021 Dec 8.
本文引用的文献
1
Can low-dose radiation therapy reduce the risk of mucormycosis in COVID-19 patients?低剂量放射疗法能否降低新冠肺炎患者毛霉菌病的风险？
J Cancer Res Ther. 2021 Oct-Dec;17(6):1294-1296. doi: 10.4103/jcrt.JCRT_2011_21.
2
Whole lung irradiation as a novel treatment for COVID-19: Interim results of an ongoing phase 2 trial in India.全肺照射作为新型冠状病毒肺炎的一种新治疗方法：印度一项正在进行的2期试验的中期结果
Radiother Oncol. 2021 Oct;163:83-90. doi: 10.1016/j.radonc.2021.08.001. Epub 2021 Aug 12.
3
Low dose radiation therapy for severe COVID-19 pneumonia: a randomized double-blind study.低剂量放射治疗重症新型冠状病毒肺炎：一项随机双盲研究。
Int J Radiat Oncol Biol Phys. 2021 May 3. doi: 10.1016/j.ijrobp.2021.04.029.
4
Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial.高剂量锌和抗坏血酸补充剂与常规治疗相比对 SARS-CoV-2 感染门诊患者症状持续时间和缓解的影响：COVID A to Z 随机临床试验。
JAMA Netw Open. 2021 Feb 1;4(2):e210369. doi: 10.1001/jamanetworkopen.2021.0369.
5
Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM): Case Report and Systematic Review of Literature.冠状病毒病（新冠-19）相关毛霉菌病（CAM）：病例报告及文献系统综述
Mycopathologia. 2021 May;186(2):289-298. doi: 10.1007/s11046-021-00528-2. Epub 2021 Feb 5.
6
Covid-19: Remdesivir has little or no impact on survival, WHO trial shows.世界卫生组织的试验表明：新冠疫情下，瑞德西韦对存活率几乎没有影响。
BMJ. 2020 Oct 19;371:m4057. doi: 10.1136/bmj.m4057.
7
Worrying situation regarding the use of dexamethasone for COVID-19.关于地塞米松用于治疗新冠肺炎的令人担忧的情况。
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620942131. doi: 10.1177/1753466620942131.
8
Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
9
Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.瑞德西韦治疗新冠病毒病-初步报告。回复。
N Engl J Med. 2020 Sep 3;383(10):994. doi: 10.1056/NEJMc2022236. Epub 2020 Jul 10.
10
Dexamethasone for COVID-19? Not so fast.地塞米松治疗 COVID-19？先别急。
J Biol Regul Homeost Agents. 2020;34(3):1241-1243. doi: 10.23812/20-EDITORIAL_1-5.
Zotero 插件